Moreover, a recent study by Udi et al.48 describes the administration of a novel peripherally restricted, orally bioavailable dual CB1 receptor/iNOS antagonist on a preclinical model of obesity-induced chronic kidney disease. This evidence concerns the gene NOS2 and obesity due to melanocortin 4 receptor deficiency.